Interface News Reporter | Zhao Meng
Interface News learned from multiple channels that Shandong Wahua Pharmaceutical Technology Co., Ltd. (referred to as Wahua Pharmaceutical, 002107.SZ) Chairman and Zhao Bingxian, known as Buffett, China, was left by relevant parties in early July 2023.
People familiar with the matter said that before, Zhao Bingxian was always in Hong Kong, and the company's affairs were performed by his remote control of his sister Zhao Caixia.After Zhao Bingxian returned to the Mainland recently, he found that he had been controlled by the side when he left. He was unpredictable and was controlled soon.
Wohua Pharmaceutical is a listed company focusing on the field of cardiovascular and cerebrovascular medicine.According to the official website information, the company was founded in 2003 and is headquartered in Weifang, Shandong. It is affiliated with Beijing SCR Wanrong Investment Group Co., Ltd., which can be traced back to Wanhetang Yaozhuang during the Qianlong period of the Qing Dynasty.The company was listed on the Shenzhen Stock Exchange in 2007.Wohua Pharmaceutical owns a number of subsidiaries, which is recognized as high -tech enterprises.
According to Wahua Medical Official Website, Zhao Bingxian was born in Beijing in November 1963. He graduated from Shanghai Jiaotong University and has a master's degree in finance. He has nearly 30 years of investment, mergers and acquisitions, reorganization of listing and business management experience.Publishing capital operation theory in January 1997 was the first domestic monograph on capital operations and investment banks. It was named the top ten bestseller in China in 1997.In 1991, he founded and served as the chairman and president of Beijing CSI Wanrong Investment Group, chairman of Beijing SCR Wanrong Pharmaceutical Investment Group, also served as chairman of Shandong Wahua Pharmaceutical Technology Co., Ltd.002293.SZ) Director of Director.
Because of the successful listing of many companies, Zhao Bingxian was nicknamed Buffett in China by a reporter from the Wall Street Journal.In 2010, Zhao Bingxian was accused of the existence of domestic violence and extramarital affairs, and fell into a divorce dispute with his wife, which was a sensation.
Article 22 of the information disclosure management measures of listed companies stipulates that the company's controlling shareholders, actual controllers, directors, supervisors, and senior management personnel are suspected of serious disciplinary violations or duties' crimes.Discovery immediately.However, as of now, Wohua Pharmaceutical has not announced information about Zhao Bingxian's separation.
The company announced the previous announcement on Zhao Bingxian on June 13, 2023.The announcement said that recently, the company received a notice from the actual controller Zhao Bingxian, and learned that the Tongzhou District People's Court issued a first trial of the property disputes on Zhao Bingxian and Lu Juan after the divorce of Zhao Bingxian and Lu Juan on June 1, 2023.Among them, the first instance judged the equity of Beijing Zhongzhong Wanrong Investment Group Co., Ltd., the controlling shareholder of the company held by the two parties.However, when the first trial was not effective, Zhao Bingxian said that he would appeal according to law.
On November 6, the interface news called Wahua Medical Administrative Department. The other party said that he did not understand that Zhao Bingxian was left, and said that he would further inquire before responding.
It is worth noting that on October 27th, Luo La Laousing Technology Co., Ltd., who served as a director, issued an announcement saying that Zhao Bingxian applied for a resignation of his company's sixth board of directors for personal reasons.Essence
